Zacks Investment Research downgraded shares of EPIZYME INC (EPZM) from OUTPERFORM to NEUTRAL on August 07, 2014, with a target price of $36.80.
Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on EPIZYME INC (EPZM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment